Details
Stereochemistry | RACEMIC |
Molecular Formula | C26H56NO5PS |
Molecular Weight | 525.765 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C
InChI
InChIKey=ODEDPKNSRBCSDO-UHFFFAOYSA-N
InChI=1S/C26H56NO5PS/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22-34-25-26(23-30-5)24-32-33(28,29)31-21-20-27(2,3)4/h26H,6-25H2,1-5H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8913844Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/14977826 | https://www.ncbi.nlm.nih.gov/pubmed/19839267 | https://www.ncbi.nlm.nih.gov/pubmed/11772309 | https://www.ncbi.nlm.nih.gov/pubmed/8135843
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8913844
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/14977826 | https://www.ncbi.nlm.nih.gov/pubmed/19839267 | https://www.ncbi.nlm.nih.gov/pubmed/11772309 | https://www.ncbi.nlm.nih.gov/pubmed/8135843
Ilmofosine (1-hexadecylthio; 2-methoxyethyl-racglycero-3-phosphocholine) is a synthetic 1-S-thioether alkyl lysophospholipid derivative with potential antineoplastic activity. In extensive preclinical evaluation against tumor cell lines and in the human tumor colony-forming assay, Ilmofosine was cytotoxic against both leukemias and solid tumors. Ilmofosine was effective against many tumor types, including ovary, non-small cell lung, kidney, and melanoma. Ilmofosine exhibited competitive inhibition of protein kinase C activity with respect to phosphatidyl-serine and inhibited the enzyme activated by diolein.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11772309 |
0.56 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14977826 |
450 mg/m² 1 times / week single, intravenous dose: 450 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
ILMOFOSINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
33.91 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14977826 |
650 mg/m² 1 times / week multiple, intravenous dose: 650 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
ILMOFOSINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
109.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14977826 |
450 mg/m² 1 times / week single, intravenous dose: 450 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
ILMOFOSINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
148.26 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14977826 |
650 mg/m² 1 times / week multiple, intravenous dose: 650 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
ILMOFOSINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
37.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14977826 |
450 mg/m² 1 times / week single, intravenous dose: 450 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
ILMOFOSINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
41.65 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14977826 |
650 mg/m² 1 times / week multiple, intravenous dose: 650 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
ILMOFOSINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8913844
300 mg/m2 per day for five days.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19839267
Promastigotes of L. donovani (1 107 parasites/mL) were cultivated in TC-199 medium supplemented with 20 % of IFCS, at which previously 38 μM of the edelfosine or miltefosine or ilmofosine had been added. After five days, the parasites were spun to 2,000 g for 10 minutes, and the pellet was washed in PBS and fixed for two hours in cacodylate buffer (0.05 M, pH 7.4) containing p-formaldehyde and glutaraldehyde (in equal shares) 2 % (v/v). Then, it was transferred for eight hours in 0.1 M cacodylate buffer with 2 % of glutaraldehyde. Postfixation was carried out for two hours with 2 % of osmium tetroxide (p/v) and potassium ferrocyanide 2 % (p/v). Once the fixation was completed, the staining of the blocks was performed with 1 % of uranyl acetate solution (p/v) for 30 minutes. Then, the blocks were dehydrated in a growing series of alcohols. The infiltration was carried out in resin Spurr for one hour and the polymerization was done in 12 hours
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C166877
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL28930
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
55008
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
5941
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
5ZZK34MC3V
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
89315-55-9
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
SUPERSEDED | |||
|
100000083704
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
83519-04-4
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
DTXSID2049008
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
DD-2
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY | |||
|
SUB08132MIG
Created by
admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY